Member Info for BuenaVista

Is it any different on Nasdaq? There seem to be lots of attempts at starting class actions as a result of claimed misinformation or misguidance affecting SP movements over there.

There's no point trying to educate Professor Eggy. He gets all his instructions, along with his payments, from Tom 'Mr Russia' Winnifrith.

You've posted timed listings like this before. Could you explain what it all means please?

They won't be presenting 3½ years (not 4) of data. The presentation will surely centre around a latest version of the corporate slide deck. They'll be summarising the current situation with AVA6000, stating clearly where they want to go with it, as well as giving the preclinical data on AVA6103 and AVA7100 (sometimes called AVA7103) to set the scene for questions and discussions with interested parties following the presentation.

Avacta is just one of dozens and dozens of small companies presenting this week. Avacta wasn't a late squeeze in - the news on Friday wasn't Earth-shattering and slots would have been allocated some time ago. Good that Avacta get one early on Wednesday - gives the rest of the day and week to network and negotiate.

Next week it is BIO-Europe Spring (Monday to Wednesday) in Milan, so hopefully Avacta will be there as well.

Fluffing

Attendance would have been organised some time ago. The late announcement of attendance was possibly because they were waiting for the Launch announcement and follow on AVA6000 update.

We'll likely be getting an updated corporate deck on the website as well.

It's a networking conference rather than a scientific conference so they'll be going over old data with a view to impress and network with the various business development professionals there.

... And you can connect at 3pm GMT if you like jamyesterday but you'll have missed the presentation. Now that would be idiotic.

The normal thing to do would be to give the GMT time in brackets after the ET time. Simples, if one thinks about one's investors.

I've seen this sort of mentality with other Americans...

No courtesy in an announcement made in the UK to state the GMT time to the British investors in a British company listed on a British market.🙄

Avacta Therapeutics to Present at the 2025 Leerink Global Healthcare Conference

LONDON and PHILADELPHIA - March 10, 2025 - Avacta Therapeutics (AIM: AVCT), a life sciences company developing next generation peptide drug conjugates (PDC) targeting powerful anti-tumor payloads directly to the tumor, today announced that the Company will present at the Leerink Global Healthcare Conference on Wednesday, March 12, 2025, at 10:00 a.m. ET in Miami.

A live webcast of the presentation will be available in the investors section of the Company's website at https://avacta.com/investors. The webcast will be archived for at least 30 days following the presentation.

Thanks Thompi.

Here's a sample paper by Dr. Anthony Yu: Cardiotoxicity of Contemporary Breast Cancer Treatments: https://pmc.ncbi.nlm.nih.gov/articles/PMC7306973/

@itsmytimenow, the subtle basher omitted to say that any listing of new, dilutive shares on Nasdaq is also highly likely to be at a significant premium to today's share price and, as there will be equivalence between the share prices on AIM and Nasdaq, that will mean that the share price here would increase proportionately and stay in step with the price on Nasdaq.

Well, that's my understanding.

The alternative to a dilutive IPO on Nasdaq would be a reverse takeover of a company already listed on Nasdaq. How would that work?

Chris Twelves became the sole Principal Investigator for the AVA6000 with the 13/12/2024 update of the ClinicalTrials record. Prior to that, all sites had a Principal Investigator and these others are now designated as Contact.

Chris Twelves' expertise is listed as "Early and late phase clinical cancer trials; Cancer pharmacology; Breast cancer". He would have been deeply involved in discussions about future plans prior to the formation of the Scientific Advisory Board and, as Principal Investigator for the trial, he will continue to be involved with all aspects of the trial.

AVA6000 Principal Investigator (Chris Twelves): https://clinicaltrials.gov/study/NCT04969835#collaborators-and-investigators

Chris Twelves bio (opened at journal publications): https://medicinehealth.leeds.ac.uk/medicine/staff/835/professor-chris-twelves#journal_article_div

I remember seeing this before. It is memorably bad. AVA6000 contains an affimer... I think they must have contracted Professor Eggy to write it.

Surprise me Ben, a Scouser is playing the victim, again?

"If you need more proof that's for you. I've seen enough and will add again now on Monday." If that was aimed at me, it's not up to me or any of us to decide how much proof is needed to show that AVA6000 is statistical efficacious, that is the decision of the regulatory authorities.

The LSE site rounds high values on both mobile and laptop. I'm surprised they have such crude roundings at high values, £3.26m -> £3m.🤷🏻‍♂️

It's not £3m, it's £6.52m if counting both trades (2 x 37.5p x 8,691,541)